Stem Cell Treatment May Calm MS Brain Inflammation
By MS Buddy ·
Summarized from Neurology(R) neuroimmunology & neuroinflammation, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Research by Laura Cooney, Paolo Muraro and 14 colleagues at Imperial College London, Hospital Universitario Ramón y Cajal and 3 other institutions in the United States, the United Kingdom and Spain.
Key Takeaway
In 24 people with severe MS, a stem cell transplant was followed by years of lower signs of inflammation and nerve damage.

What They Found
Researchers followed 24 people with severe MS after a transplant that uses their own stem cells to rebuild the immune system. For several years, blood and spinal fluid tests showed lower levels of many substances linked to inflammation. A marker of nerve damage also fell, which fits with the disease becoming less active. Two substances in spinal fluid rose instead, and researchers do not yet know what those changes mean. Blood and spinal fluid often told different stories, much like checking the weather outside does not always tell you what it feels like inside a house.
Who Should Care and Why
People with severe MS and their caregivers may find this study useful when discussing treatment options with an MS specialist. It offers clues about what happens inside the body after this transplant, rather than showing only whether symptoms or scans change. Healthcare providers may need both blood and spinal fluid tests to understand those changes more fully. A spinal fluid test requires a needle in the lower back, so its possible value must be weighed against the burden of the test. These findings do not call for a change to your daily care routine, but they can help you ask what a test result can and cannot tell you.
Important Considerations
The study included only 24 people with severe MS, so its results may not apply to everyone with MS. It tracked changes after treatment but cannot prove that lower test markers will lead to better symptoms for any one person. Some markers rose, and the meaning of those changes needs more study.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Neurology(R) neuroimmunology & neuroinflammation by et al.. Reproduced from the PubMed record.
Autologous hematopoietic stem cell transplantation (AHSCT) can induce long-lasting immune tolerance and disease quiescence in patients with severe multiple sclerosis (MS), but the underlying mechanisms are not well understood. We hypothesized that AHSCT would induce persistent decreases in inflammatory cytokines, chemokines, and axoglial damage biomarkers in serum and CSF. Longitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48. Approximately 50 soluble biomarkers were analyzed to determine treatment-induced changes and associations with disease activity, including clinical and MRI parameters. AHSCT resulted in decreased expression of many proinflammatory cytokines, chemokines, and neuroinflammatory markers for several years in both serum and CSF, including neurofilament light chain (NfL). CSF levels of glial fibrillary acid protein and IL-7, on the contrary, increased after treatment. Expansion of cytomegalovirus and/or Epstein-Barr virus early after AHSCT resulted in transient increases in inflammatory cytokines in serum, but these changes did not persist. Changes in serum were largely distinct from changes in CSF, and concentrations of cytokines and chemokines in serum rarely correlated with concentrations in CSF, except for NfL. These results confirm the hypothesis that AHSCT results in long-lasting reductions in inflammatory cytokines, chemokines, and axoglial damage markers, consistent with persistent disease quiescence. The lack of relationships between biomarkers in serum and CSF suggests that these samples largely reflect distinct immunologic processes and compartments, and that analysis of CSF may be warranted for deeper understanding of disease processes in the CNS despite the challenges associated with performing lumbar punctures. Expression of IL-7 in CSF may be an underappreciated biomarker of the inflammatory state in the CNS and warrants further study.
Explore more research
Related MS research

11/20/2026
A review looks at changes in how the body uses tryptophan (a building block of proteins) in MS and o
Read More
11/19/2026
Five people with MS received engineered immune cells. Spinal fluid immune changes were seen, but saf
Read More
11/19/2026
A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/20/2026
A small study followed brain connections and thinking in early MS over 10 months. Patterns differed
Read More
11/20/2026
A global study including childhood MS found rising rates and disability from rare childhood brain an
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
